Detailansicht

Wissensnetz

Person

Nicola Polverelli

Name	Nicola Polverelli
Ort	Pavia (Wirkungsort) Italien
Akademischer Grad bzw. Titel	MD, PhD
Beziehung	Università di Bologna (Promotion) (2015-2018)
Quelle	https://www.linkedin.com/in/nicola-polverelli-410513107/ (Stand: 05.08.2024)
Datensatztyp	Person
GND-Nummer	1337896381
Datensatz-ID	1337896381
Beteiligt an alle anzeigen Navigating ‘grey areas’ and challenges during evaluation of transplant eligibility in specific myelofibrosis populations: a perspective on behalf of the Chronic Malignancies Working Party of the EBMT Correction: Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT Correction: CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation Correction: Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French–Italian 10-year experience on 228 patients RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? Exosomes in Chronic Myeloid Leukemia: Are We Reading a New Reliable Message? Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Nicola Polverelli

Navigating ‘grey areas’ and challenges during evaluation of transplant eligibility in specific myelofibrosis populations: a perspective on behalf of the Chronic Malignancies Working Party of the EBMT

Correction: Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT

Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT

Correction: CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation

CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation

Correction: Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French–Italian 10-year experience on 228 patients

RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients?

Exosomes in Chronic Myeloid Leukemia: Are We Reading a New Reliable Message?

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib